HYFT offers high-upside techbio optionality as recurring AI licensing scales, but cash burn and execution risk make the $1.46 stock highly speculative.
Overview
MindWalk Holdings Corp. (NASDAQ: HYFT), historically ImmunoPrecise Antibodies, is consolidating its antibody discovery services, BioStrand data technology, and Talem Therapeutics pipeline under an enterprise AI model. The September 2025 rebrand and ticker change represent a strategic pivot from project-based wet-lab CRO work toward scalable LensAI and ReefIQ software, supported by in-house validation laboratories. Its principal differentiation is a closed-loop architecture: 660 million biological patterns and 25 billion relationships constrain computational outputs before wet-lab testing, addressing the folding, manufacturability, and biological “hallucination” problems of standalone models. The company works with 19 of the top 20 global pharmaceutical developers and signed its first two contracted recurring LensAI agreements in FY2026. **Financial momentum is improving:** FY2026 continuing revenue rose 46.4% to C$15.558 million, gross margin expanded to 58.8%, and the continuing net loss narrowed to C$15.102 million from C$33.147 million. At $1.46, valuation is 5.9x trailing sales and 5.0x EV/sales, below cited techbio peers trading at 7.3x–11.4x sales. Near-term catalysts include additional enterprise licensing, ReefIQ revenue, preclinical validation, partnerships, and European patent progress, although execution, cash burn, and dilution keep the stock speculative.